Usefulness of intravascular ultrasound to predict outcomes in short-length lesions treated with drug-eluting stents

Young Won Yoon, Sanghoon Shin, Byeong Keuk Kim, Jung Sun Kim, Dong Ho Shin, Young Guk Ko, Donghoon Choi, Dong Woon Jeon, Hyuckmoon Kwon, Yangsoo Jang, Myeongki Hong

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Intravascular ultrasound (IVUS) offers tomographic images of the coronary artery, helping physicians to refine drug-eluting stent (DES) implantation in angiographically complex lesions. However, controversy exists regarding whether the routine use of IVUS in short-length lesions leads to improved clinical outcomes after DES implantation. Therefore, we evaluated the usefulness of IVUS in predicting major adverse cardiac events (MACE), including cardiovascular death, myocardial infarction, or target vessel revascularization, at 1 year after DES implantation in short-length lesions. The present study was a subanalysis of the REal Safety and Efficacy of a 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation (RESET) study with different clinical outcome parameters. The study population consisted of 662 patients with IVUS guidance and 912 patients with angiography guidance who underwent DES implantation (stent length ≤24 mm). In the IVUS-guided group, adjuvant postdilation was more frequently performed (43.0% vs 34.6%, p <0.001), and the postintervention minimal lumen diameters were greater (2.88 ± 0.44 mm vs 2.72 ± 0.43 mm, p <0.001). MACE occurred in 15 IVUS-guided (2.3%) and 19 angiographically guided (2.1%) patients (p = 0.872). In a subset of patients with diabetes mellitus (n = 292), the MACE rate was 3.4% (n = 4) and 1.7% (n = 3) in the IVUS- and angiographically guided patients, respectively (p = 0.384). The MACE rate in the IVUS- and angiographically guided patients with acute coronary syndrome (n = 601) was 1.1% (n = 3) and 2.7% (n = 9), respectively (p = 0.194). The clinical benefits of IVUS-guided DES implantation compared with angiographically guided DES implantation in short-length lesions could not be confirmed even in patients with clinically high-risk presentations (acute coronary syndrome and diabetes mellitus). In conclusion, routine IVUS guidance does not provide clinical benefits when performing short-length DES implantation.

Original languageEnglish
Pages (from-to)642-646
Number of pages5
JournalAmerican Journal of Cardiology
Volume112
Issue number5
DOIs
Publication statusPublished - 2013 Sep 1

Fingerprint

Drug-Eluting Stents
Acute Coronary Syndrome
Stents
Diabetes Mellitus
Coronary Vessels
Angiography
Myocardial Infarction
Physicians
Safety
Population

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Yoon, Young Won ; Shin, Sanghoon ; Kim, Byeong Keuk ; Kim, Jung Sun ; Shin, Dong Ho ; Ko, Young Guk ; Choi, Donghoon ; Jeon, Dong Woon ; Kwon, Hyuckmoon ; Jang, Yangsoo ; Hong, Myeongki. / Usefulness of intravascular ultrasound to predict outcomes in short-length lesions treated with drug-eluting stents. In: American Journal of Cardiology. 2013 ; Vol. 112, No. 5. pp. 642-646.
@article{a29938f1ebbf4195aca14d38b9178b88,
title = "Usefulness of intravascular ultrasound to predict outcomes in short-length lesions treated with drug-eluting stents",
abstract = "Intravascular ultrasound (IVUS) offers tomographic images of the coronary artery, helping physicians to refine drug-eluting stent (DES) implantation in angiographically complex lesions. However, controversy exists regarding whether the routine use of IVUS in short-length lesions leads to improved clinical outcomes after DES implantation. Therefore, we evaluated the usefulness of IVUS in predicting major adverse cardiac events (MACE), including cardiovascular death, myocardial infarction, or target vessel revascularization, at 1 year after DES implantation in short-length lesions. The present study was a subanalysis of the REal Safety and Efficacy of a 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation (RESET) study with different clinical outcome parameters. The study population consisted of 662 patients with IVUS guidance and 912 patients with angiography guidance who underwent DES implantation (stent length ≤24 mm). In the IVUS-guided group, adjuvant postdilation was more frequently performed (43.0{\%} vs 34.6{\%}, p <0.001), and the postintervention minimal lumen diameters were greater (2.88 ± 0.44 mm vs 2.72 ± 0.43 mm, p <0.001). MACE occurred in 15 IVUS-guided (2.3{\%}) and 19 angiographically guided (2.1{\%}) patients (p = 0.872). In a subset of patients with diabetes mellitus (n = 292), the MACE rate was 3.4{\%} (n = 4) and 1.7{\%} (n = 3) in the IVUS- and angiographically guided patients, respectively (p = 0.384). The MACE rate in the IVUS- and angiographically guided patients with acute coronary syndrome (n = 601) was 1.1{\%} (n = 3) and 2.7{\%} (n = 9), respectively (p = 0.194). The clinical benefits of IVUS-guided DES implantation compared with angiographically guided DES implantation in short-length lesions could not be confirmed even in patients with clinically high-risk presentations (acute coronary syndrome and diabetes mellitus). In conclusion, routine IVUS guidance does not provide clinical benefits when performing short-length DES implantation.",
author = "Yoon, {Young Won} and Sanghoon Shin and Kim, {Byeong Keuk} and Kim, {Jung Sun} and Shin, {Dong Ho} and Ko, {Young Guk} and Donghoon Choi and Jeon, {Dong Woon} and Hyuckmoon Kwon and Yangsoo Jang and Myeongki Hong",
year = "2013",
month = "9",
day = "1",
doi = "10.1016/j.amjcard.2013.04.037",
language = "English",
volume = "112",
pages = "642--646",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

Usefulness of intravascular ultrasound to predict outcomes in short-length lesions treated with drug-eluting stents. / Yoon, Young Won; Shin, Sanghoon; Kim, Byeong Keuk; Kim, Jung Sun; Shin, Dong Ho; Ko, Young Guk; Choi, Donghoon; Jeon, Dong Woon; Kwon, Hyuckmoon; Jang, Yangsoo; Hong, Myeongki.

In: American Journal of Cardiology, Vol. 112, No. 5, 01.09.2013, p. 642-646.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Usefulness of intravascular ultrasound to predict outcomes in short-length lesions treated with drug-eluting stents

AU - Yoon, Young Won

AU - Shin, Sanghoon

AU - Kim, Byeong Keuk

AU - Kim, Jung Sun

AU - Shin, Dong Ho

AU - Ko, Young Guk

AU - Choi, Donghoon

AU - Jeon, Dong Woon

AU - Kwon, Hyuckmoon

AU - Jang, Yangsoo

AU - Hong, Myeongki

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Intravascular ultrasound (IVUS) offers tomographic images of the coronary artery, helping physicians to refine drug-eluting stent (DES) implantation in angiographically complex lesions. However, controversy exists regarding whether the routine use of IVUS in short-length lesions leads to improved clinical outcomes after DES implantation. Therefore, we evaluated the usefulness of IVUS in predicting major adverse cardiac events (MACE), including cardiovascular death, myocardial infarction, or target vessel revascularization, at 1 year after DES implantation in short-length lesions. The present study was a subanalysis of the REal Safety and Efficacy of a 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation (RESET) study with different clinical outcome parameters. The study population consisted of 662 patients with IVUS guidance and 912 patients with angiography guidance who underwent DES implantation (stent length ≤24 mm). In the IVUS-guided group, adjuvant postdilation was more frequently performed (43.0% vs 34.6%, p <0.001), and the postintervention minimal lumen diameters were greater (2.88 ± 0.44 mm vs 2.72 ± 0.43 mm, p <0.001). MACE occurred in 15 IVUS-guided (2.3%) and 19 angiographically guided (2.1%) patients (p = 0.872). In a subset of patients with diabetes mellitus (n = 292), the MACE rate was 3.4% (n = 4) and 1.7% (n = 3) in the IVUS- and angiographically guided patients, respectively (p = 0.384). The MACE rate in the IVUS- and angiographically guided patients with acute coronary syndrome (n = 601) was 1.1% (n = 3) and 2.7% (n = 9), respectively (p = 0.194). The clinical benefits of IVUS-guided DES implantation compared with angiographically guided DES implantation in short-length lesions could not be confirmed even in patients with clinically high-risk presentations (acute coronary syndrome and diabetes mellitus). In conclusion, routine IVUS guidance does not provide clinical benefits when performing short-length DES implantation.

AB - Intravascular ultrasound (IVUS) offers tomographic images of the coronary artery, helping physicians to refine drug-eluting stent (DES) implantation in angiographically complex lesions. However, controversy exists regarding whether the routine use of IVUS in short-length lesions leads to improved clinical outcomes after DES implantation. Therefore, we evaluated the usefulness of IVUS in predicting major adverse cardiac events (MACE), including cardiovascular death, myocardial infarction, or target vessel revascularization, at 1 year after DES implantation in short-length lesions. The present study was a subanalysis of the REal Safety and Efficacy of a 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation (RESET) study with different clinical outcome parameters. The study population consisted of 662 patients with IVUS guidance and 912 patients with angiography guidance who underwent DES implantation (stent length ≤24 mm). In the IVUS-guided group, adjuvant postdilation was more frequently performed (43.0% vs 34.6%, p <0.001), and the postintervention minimal lumen diameters were greater (2.88 ± 0.44 mm vs 2.72 ± 0.43 mm, p <0.001). MACE occurred in 15 IVUS-guided (2.3%) and 19 angiographically guided (2.1%) patients (p = 0.872). In a subset of patients with diabetes mellitus (n = 292), the MACE rate was 3.4% (n = 4) and 1.7% (n = 3) in the IVUS- and angiographically guided patients, respectively (p = 0.384). The MACE rate in the IVUS- and angiographically guided patients with acute coronary syndrome (n = 601) was 1.1% (n = 3) and 2.7% (n = 9), respectively (p = 0.194). The clinical benefits of IVUS-guided DES implantation compared with angiographically guided DES implantation in short-length lesions could not be confirmed even in patients with clinically high-risk presentations (acute coronary syndrome and diabetes mellitus). In conclusion, routine IVUS guidance does not provide clinical benefits when performing short-length DES implantation.

UR - http://www.scopus.com/inward/record.url?scp=84881613656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881613656&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2013.04.037

DO - 10.1016/j.amjcard.2013.04.037

M3 - Article

C2 - 23711810

AN - SCOPUS:84881613656

VL - 112

SP - 642

EP - 646

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -